Thad T Sharp

US Patent:

20190264206, Aug 29, 2019

Filed:

Mar 12, 2019

Appl. No.:

16/299692

Inventors:

- Iowa City IA, US
Brad Amendt - Iowa City IA, US
Thad Sharp - Iowa City IA, US
Aliasger Salem - Iowa City IA, US

Assignee:

UNIVERSITY OF IOWA RESEARCH FOUNDATION - Iowa City IA

International Classification:

C12N 15/113
A61K 9/00
A61K 9/51
A61K 31/713
A61L 27/24
A61L 27/54
A61K 9/16
C12N 7/00
A61L 27/56

Abstract:

In certain embodiments, the present invention provides the use of microRNA (miR)-200a to inhibit ossification and bone formation.

US Patent:

20190144856, May 16, 2019

Filed:

Jan 15, 2016

Appl. No.:

15/543816

Inventors:

- Iowa City IA, US
Brad A. AMENDT - Solon IA, US
Aliasger K. SALEM - Coralville IA, US
Satheesh ELANGOVAN - Iowa City IA, US
Gustavo Avila Ortiz - Iowa City IA, US
Thad SHARP - Chapel Hill NC, US

Assignee:

University of Iowa Research Foundation - Iowa City IA

International Classification:

C12N 15/113
A61P 19/04
A61P 19/02
A61K 47/14
A61K 47/18
A61K 47/34

Abstract:

Compositions and methods to prevent, inhibit or treat aveolar or periodontal bone loss, enhance bone regeneration, prevent, inhibit or treat peri-implantitis or periodontitis, e.g., periodontitis or peri-implantitis associated with bone loss, or to prevent, inhibit or treat osteoarthritis are provided.

US Patent:

20170321190, Nov 9, 2017

Filed:

Aug 13, 2015

Appl. No.:

15/526282

Inventors:

- Iowa City IA, US
Thad Sharp - Iowa City IA, US

Assignee:

UNIVERSITY OF IOWA RESEARCH FOUNDATION - Iowa City IA

International Classification:

C12N 5/077
A61K 35/28

Abstract:

The invention provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) transfecting the de-differentiated cell with an expression cassette comprising a promoter operably linked to a nucleic acid encoding a conversion agent to form a re-programmed differentiated cell. The invention also provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) contacting the de-differentiated cell with a conversion agent to form a re-programmed differentiated cell. The invention provides in certain embodiments, re-programmed differentiated epithelial cells, and methods of using these re-programmed differentiated epithelial cells to repair or re-generate tissue in vivo.

US Patent:

20170314020, Nov 2, 2017

Filed:

May 1, 2017

Appl. No.:

15/583564

Inventors:

- IOWA CITY IA, US
Brad Amendt - Iowa City IA, US
Thad Sharp - Iowa City IA, US
Aliasger Salem - Iowa City IA, US

Assignee:

UNIVERSITY OF IOWA RESEARCH FOUNDATION - IOWA CITY IA

International Classification:

C12N 15/113
A61K 31/713
C12N 7/00
A61L 27/54
A61L 27/56
A61K 9/16
A61K 9/16
A61L 27/24
A61K 48/00

Abstract:

In certain embodiments, the present invention provides the use of microRNA (miR)-200a and/or miR-200c to inhibit ossification and bone formation. In certain embodiments, the present invention provides the use of miR-200a inhibitor to stimulate bone regeneration.

US Patent:

20140094461, Apr 3, 2014

Filed:

Apr 3, 2012

Appl. No.:

14/122264

Inventors:

Raj Bandaru - Winchester MA, US
Asifa Haider - Succasunna NJ, US
Douglas Michael Robinson - Hanover MA, US
Kristine Lynn Rose - Randolph NJ, US
Thad Tyson Sharp - Iowa City IA, US
Yaping Shou - Acton MA, US

International Classification:

C12Q 1/68
A61K 31/5377

US Classification:

5142355, 435 612

Abstract:

A method of selecting a subject having cancer for treatment with a Hedgehog signaling inhibitor by determining the level of expression of at least one biomarker in a biological sample derived from the subject.